生长抑素受体显像剂在神经内分泌肿瘤中的临床研究进展  

Clinical research progress of somatostatin receptor imaging agents in neuroendocrine tumors

作　　者：冯柳 吴爽[1] 金晨涛 田梅[1] Feng Liu;Wu Shuang;Jin Chentao;Tian Mei(Department of Nuclear Medicine,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China)

机构地区：[1]浙江大学医学院附属第二医院核医学科,杭州310009

出　　处：《国际放射医学核医学杂志》2021年第6期376-382,共7页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：神经内分泌肿瘤(NETs)是一类起源于神经内分泌细胞的异质恶性肿瘤,分化良好的NETs可过度表达生长抑素受体(SSTR)。放射性同位素标记的生长抑素类似物与SSTR的特异性结合可实现NETs的功能成像,对NETs的诊断及其患者的临床管理具有重要意义。近年来,研究者已成功研发出多种靶向SSTR的示踪剂并应用于临床,笔者总结了用于SPECT和PET的SSTR显像剂在NETs中的临床应用及其研究进展。Neuroendocrine tumors(NETs)are a type of heterogeneous malignancies originating from the neuroendocrine system.Well-differentiated NETs can express high levels of somatostatin receptor(SSTR).Radioisotope-labeled somatostatin analogue can realize functional imaging in NETs by specifically binding to SSTR,which is crucial for the diagnosis and clinical management of NETs patients.In recent years,a variety of tracers targeting SSTR have been developed successfully,paving the avenue towards the precision medicine in NETs.The authors summarizs the development of SSTR imaging agents for SPECT or PET and their clinical applications in NETs.

关 键 词：神经内分泌瘤 受体 生长抑素 正电子发射断层显像术 体层摄影术 发射型计算机 单光子 

分 类 号：R739.4[医药卫生—肿瘤]